Hsbc Holdings PLC Sells 25,935 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Hsbc Holdings PLC cut its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 61.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,497 shares of the company's stock after selling 25,935 shares during the period. Hsbc Holdings PLC's holdings in Hims & Hers Health were worth $405,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of HIMS. Vanguard Group Inc. grew its holdings in Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after purchasing an additional 2,020,722 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after acquiring an additional 1,562,302 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after acquiring an additional 4,145,305 shares during the period. Geode Capital Management LLC increased its holdings in shares of Hims & Hers Health by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after acquiring an additional 40,447 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Hims & Hers Health by 7.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company's stock valued at $43,448,000 after acquiring an additional 129,416 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Soleil Boughton sold 3,236 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $27.77, for a total transaction of $89,863.72. Following the completion of the transaction, the insider now directly owns 170,285 shares in the company, valued at $4,728,814.45. This represents a 1.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Irene Becklund sold 2,203 shares of the firm's stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total transaction of $63,402.34. Following the completion of the sale, the insider now owns 8,007 shares in the company, valued at $230,441.46. This represents a 21.58 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 650,500 shares of company stock worth $25,790,311 in the last ninety days. 17.71% of the stock is owned by insiders.

Hims & Hers Health Price Performance

HIMS traded up $0.64 on Friday, hitting $52.04. 61,754,901 shares of the stock were exchanged, compared to its average volume of 18,273,157. The firm has a market capitalization of $11.56 billion, a price-to-earnings ratio of 118.28 and a beta of 1.84. Hims & Hers Health, Inc. has a 12 month low of $12.07 and a 12 month high of $72.98. The business has a 50-day moving average of $32.74 and a two-hundred day moving average of $32.16.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. During the same quarter last year, the business posted $0.05 EPS. The firm's revenue for the quarter was up 110.7% on a year-over-year basis. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on HIMS. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. TD Cowen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their price target for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Morgan Stanley reduced their price objective on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a report on Tuesday, April 29th. Truist Financial decreased their target price on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Finally, Citigroup reissued a "sell" rating and set a $30.00 price target (up from $25.00) on shares of Hims & Hers Health in a report on Tuesday. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $37.67.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.